The significant EPS miss and widening losses are bearish, but the strong cash position and positive clinical data may provide a floor. Monitor upcoming Phase 2b data readouts for EP-104GI; any efficacy or safety signals could drive volatility. The $63.2M offering at $7.00/share creates a reference price near current levels.
Price Chart
Executive Summary
Eupraxia reported Q1 2026 EPS of -$0.37, a 91.5% miss vs consensus of -$0.19, with net loss widening to $12.7M from $6.8M a year ago due to doubled R&D costs. The company highlighted positive 36-week tissue health and symptom data from its RESOLVE trial and a $63.2M public offering, ending the quarter with $138.9M in cash and investments, sufficient into H2 2028.
Key Financial Metrics
Key Facts
- Q1 2026 EPS of -$0.37 missed consensus of -$0.19 by 91.5%
- Net loss widened to $12.7M from $6.8M in Q1 2025, driven by doubled R&D costs for the RESOLVE trial
- Cash and investments totaled $138.9M as of March 31, 2026, up from $80.6M at year-end 2025
- Closed $63.2M public offering in February 2026, issuing 7.6M shares at $7.00/share
- Positive 36-week tissue health and symptom data reported from highest dose cohort in Phase 1b/2a RESOLVE trial for EoE
- Company expects cash runway into H2 2028
Financial Impact
EPS miss of $0.18 vs consensus; net loss increased by $5.9M YoY
Risk Factors
- Clinical trial failure or delays in RESOLVE trial
- Further dilution from warrant exercises or additional offerings
- Tariff impact on manufacturing costs
- Cash burn rate may accelerate if trials expand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293518 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 6-K | $7.59 | awaiting T+5 | — | $6.85 (−9.75%) |
Oct 15, 2026 11d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $6.85 (+1.18%) |
Oct 9, 2026 17d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $6.85 (−8.18%) |
Sep 30, 2026 26d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Sep 30, 2026 26d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $6.85 (−24.73%) |
Aug 25, 2026 8w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $6.85 (+7.68%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $6.85 (+2.70%) |
Aug 11, 2026 10w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $6.85 (+5.71%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $6.85 (+5.06%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $6.85 (+3.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers